Soligenix Inc (SNGX)

[someday7]

Soligenix (OTCQB:SNGX +3.4%) initiates a development agreement with Emergent BioSolutions (EBS +0.4%) to implement a commercially viable, scalable production technology for RiVax, an investigational vaccine candidate to protect against ricin exposure. It will transfer the manufacturing processes and analytics to EBS to conduct further development that could lead to a commercial manufacturing collaboration.

This was May of 15. The following is a new collaboration. What happened at Emergent? Does Management care to fill in the blank.


Princeton, NJ – December 20, 2016 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has extended its collaboration with IDT Biologika (hereafter referred to as IDT) for the manufacture of RiVax™, the Company’s proprietary heat-stable ricin toxin vaccine. Under the terms of the collaboration, Soligenix will scale-up the formulation/filling processes and continue development and validation of analytical methods established at IDT to advance the program towards a commercially viable scalable technology for the RiVax™ vaccine product compliant with current Good Manufacturing Practices (cGMPs).